BARDINA, VALENTINA

BARDINA, VALENTINA  

SCIENZE CLINICHE E BIOLOGICHE  

Mostra records
Risultati 1 - 20 di 35 (tempo di esecuzione: 0.022 secondi).
Titolo Data di pubblicazione Autore(i) File
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. 2011 Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity 2017 Alchera, E;Rolla, S; Imarisio, C; Bardina, V; Valente, G; Novelli, F; Carini, R
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 2016 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 2016 Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 2016 De Mercanti, Stefania; Rolla, Simona; Cucci, Angele; Bardina, Valentina; Cocco, Eleonora; Vladic, Anton; Soldo-Butkovic, Silva; Habek, Mario; Adamec, Ivan; Horakova, Dana; Annovazzi, Pietro; Novelli, Francesco; Durelli, Luca; Clerico, Marinella
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 2012 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study 2018 Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M
The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice 2016 Rolla, Simona; Alchera, Elisa; Imarisio, Chiara; Bardina, Valentina; Valente, Guido; Cappello, Paola; Mombello, Cristina; Follenzi, Antonia; Novelli, Francesco; Carini, Rita
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation 2017 Iannello A., Ferrero G., Maglione A., Cordero F., Rolla S., Bardina V., De Mercanti S., Durelli L., Clerico M., Cutrupi S.
Circulating T helper 22 cells increase in multiple sclerosis patients:phenotypical and functional characterization. 2011 Simona Rolla ; Marinella Clerico; Valentina Bardina; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis. 2018 Rolla Simona, Bardina Valentina, Iannello Andrea, Maglione Alessandro, De Mercanti Stefania, Puorro Giorgia, Lanzillo Roberta, Cordioli Cinzia, Turrini Mariavittoria, De Bortoli Michele, Cutrupi Santina, Clerico Marinella.
Epigenetic signature in T helper 17 and regulatory T cells in multiple sclerosis patients during pregnancy 2018 Andrea Iannello, Alessandro Maglione, Giulio Ferrero, Simona Rolla, Valentina Bardina, Francesca Cordero, Michele De Bortoli, Marinella Clerico, Santina Cutrupi
Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study 2017 Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Ferraro, M; Cianflone, A; Lanzillo, R; Durelli, L; Cocolin, LS; Clerico, M
Gut microbiota and metagenomic diversity in Clinical Isolated Syndrome 2018 Rolla, S; Ferrocino, I; Bardina, V; Ferraro, M; Cianflone, A; Lanzillo, R; De Mercanti, S; Cocolin, L; Clerico, M
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 2014 S De Mercanti ; M Clerico ; S Rolla ; V Bardina ; M.A Cucci ; D Taverna ; D Cimino ; F Piazza ; E Virgilio ; D Armocida ; M Basso ; A Vladic ; M Habek ; I Adamec ; V Brinar ; E Cocco ; J Frau ; P Annovazzi ; D Horàkovà ; I Kovàrovà ; F Novelli ; L Durelli
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study 2017 Clerico, M; Signori, A; De Mercanti, S; Artusi, CA; Maniscalco, GT; Carotenuto, A; Lanzillo, R; Esposito, S; Capuano, R; Bonavita, S; Lorefice, L; Cocco, E; Annovazzi, P; Baroncini, D; Zaffaroni, M; Vercellino, M; Trebini, C; Cavalla, P; Clerici, VT; Bardina, V; Rolla, S; Durelli, L; Sormani, MP
In Human Multiple sclerosis, T helper 17 lymphocytes display increased levels of JAK2 that stabilize cell surface IFN-YR2chain 2010 Simona Rolla; Laura Conti; Raffaele De Palma; Daniela Boselli; Valentina Bardina; Gabriella Rodolico; Olli Silveinnonen; Marinella Clerico; Luca Durelli; Francesco Novelli
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses 2017 Rolla, Simona; De Mercanti, Stefania Federica; Bardina, Valentina; Horakova, Dana; Habek, Mario; Adamec, Ivan; Cocco, Eleonora; Annovazzi, Pietro; Vladic, Anton; Novelli, Francesco; Durelli, Luca; Clerico, Marinella
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function 2015 De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Vacca, A; Cocco, E; Vladic, A; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Edan, G; Durelli, L; Clerico, M
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up 2022 Rolla S.; De Mercanti S.F.; Bardina V.; Maglione A.; Taverna D.; Novelli F.; Cocco E.; Vladic A.; Habek M.; Adamec I.; Annovazzi P.O.L.; Horakova D.; Clerico M.